Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Folfirinox plus Sintilimab for Metastatic ICC
NCT04398927Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- May 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University. Planned start May 2020; status: withdrawn.
02
Drugs
sintilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04398927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398927.